ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2024
Macrolide-resistant
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Antimicrobial resistance inEpidemiology and infection · 2026Pooled it
- Immunological insights into why pertussis continues to be endemic.Human vaccines & immunotherapeutics · 2026Review
- Epidemiological burden of pertussis in children in Asia: a review of 1990-2021 data and future projections.Translational pediatrics · 2026Article
- The evolution of pertactin expression in Belgian circulatingMicrobiology spectrum · 2026Article
- Epidemiological and clinical characteristics of macrolide-resistant Bordetella pertussis in southern China: an 8-year retrospective study.BMC infectious diseases · 2026Article
- Effectiveness and impact of the 2-component acellular pertussis vaccine as a preschool booster in Finland - A register-based study.PLOS global public health · 2026Article
- Understanding the Epidemiology and Contributing Factors of Post-COVID-19 Pertussis Outbreaks: A Narrative Review.Infectious diseases and therapy · 2026Review
- Pertussis is identified among common respiratory diseases: A case report.SAGE open medical case reports · 2026Article
- Revisiting Whooping Cough: Global Drivers and Implications of Pertussis Resurgence in the Acellular Vaccine Era.Vaccines · 2025Review
- Genomic surveillance reveals global spread of macrolide-resistantJournal of clinical microbiology · 2025Article
- [Clinical characteristics of trimethoprim-sulfamethoxazole-induced rash during treatment of pertussis in children].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Article
- Absence of Macrolide-Resistant Mutations inOpen forum infectious diseases · 2025Article
- Resurgence of pertussis: whopping the '100-day cough'.Current opinion in pediatrics · 2025Review
- Effect of Early Administration of Clarithromycin or Azithromycin on Symptoms of Pertussis in Infants.Antibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since April 2024, a pertussis epidemic has been ongoing in Finland with 2,215 notified cases by end October. Of them, 30.1% (n = 667) were aged 10-14 years. Of the 462
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.